Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 711

Results For "IT"

10376 News Found

USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent
Drug Approval | October 26, 2023

USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent

The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer


Venus Remedies earns REO Certification from CII for second consecutive year
News | October 26, 2023

Venus Remedies earns REO Certification from CII for second consecutive year

The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)


Nanoform grant global starmap AI license to AstraZeneca
Digitisation | October 25, 2023

Nanoform grant global starmap AI license to AstraZeneca

Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening


Natco Pharma receives 8 observations from USFDA for Pharma Division at Kothur
Drug Approval | October 23, 2023

Natco Pharma receives 8 observations from USFDA for Pharma Division at Kothur

The company is confident of addressing all the observations within the stipulated time


RPG Life Sciences posts Q2 FY24 PAT at Rs. 25.86 Cr
News | October 23, 2023

RPG Life Sciences posts Q2 FY24 PAT at Rs. 25.86 Cr

RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023


Indoco Remedies posts consolidated Q2FY24 PAT at Rs. 35.08 Cr
News | October 23, 2023

Indoco Remedies posts consolidated Q2FY24 PAT at Rs. 35.08 Cr

The company has reported total income of Rs. 486.16 crores during the period ended September 30, 2023


Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA
Drug Approval | October 23, 2023

Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA

CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases


FDA approves only vaccine Penbraya for treatment of meningococcal disease in adolescents
Drug Approval | October 21, 2023

FDA approves only vaccine Penbraya for treatment of meningococcal disease in adolescents

The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease


Evonik strengthens nanoparticle technologies and services portfolio for parenteral drug delivery
News | October 21, 2023

Evonik strengthens nanoparticle technologies and services portfolio for parenteral drug delivery

Three block copolymers added to RESOMER portfolio of bioabsorbable polymers


Laurus Labs Q2 FY24 consolidated PAT up QOQ at Rs. 36.95 Cr
News | October 21, 2023

Laurus Labs Q2 FY24 consolidated PAT up QOQ at Rs. 36.95 Cr

Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023